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Abstract
Background: PCA3 (prostate cancer antigen 3) gene is one of the most prostate cancer-specific genes at present.
Consequently, the prostate-specific expression and the sharp up-regulation of PCA3 mRNA in prostate cancer suggest a
unique transcriptional regulation, which possibly can be attributed to promoter polymorphism. In our study, we evaluated
whether there is polymorphism in PCA3 promoter region and also assess the association of the polymorphism with prostate
cancer.
Methodology/Principal Findings: We designed a specific primer set to screen the promoter of PCA3 gene by polymerase
chain reaction (PCR)-based cloning and sequencing with the DNA extracted from peripheral blood samples of prostate
cancer (PCa) cases (n=186) and healthy control cases (n=135). Genotype-specific risks were estimated as odds ratios (ORs)
with associated 95% confidence intervals (CIs) by chi-square test. Possible deviation of the genotype frequencies from
controls and PCa cases expected under Hardy-Weinberg equilibrium was assessed by the chi-square test. Short tandem
repeat polymorphism of TAAA was found in the promoter region of PCA3 gene, five polymorphisms and eight genotypes
were identified. The eight genotypes were divided into three groups: #10TAAA,1 1 TAAA, $12TAAA. The group 11TAAA and
$12TAAA were associated with higher relative risk for prostate cancer than group #10TAAA (OR=1.76, 95%CI=1.07–
2.89[for group 11TAAA]; OR=5.28, 95%CI=1.76–15.89[for group $12TAAA]).
Conclusions/Significance: The presence of the (TAAA)n short tandem repeat polymorphisms in the PCA3 promoter region
may be a risk factor for prostate cancer in the Chinese population.
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Introduction
Prostate cancer is the most commonly diagnosed malignancy
and the second leading cause of cancer-related deaths in the
Western male population [1], and its incidence is still increasing.
PCa can be cured by radical surgery or radiation therapy if the
disease is localized within the prostate[2–5]. However, when this
carcinoma has spread locally or distantly, no curative therapy can
be offered, and these patients will suffer from a poor prognosis
[6,7]. Therefore, there is an urgent need for early diagnosis of the
disease to increase the cure rate for PCa.
Although serum prostate-specific antigen (PSA) measurement is
regarded as the best conventional serum tumor marker available,
there is not enough specificity and sensitivity for PSA in detecting
prostate cancer early. For example, PSA is often elevated in
benign prostatic hyperplasia and prostatitis. Further, the Prostate
Cancer Prevention Trial showed that even in patients with PSA
levels ,4 ng/ml, .15% had biopsy detectable prostate cancer[8].
More prostate cancer specific and sensitive biomarkers are
urgently needed. Recently, Bussemakers et al. reported a novel
prostate-specific gene, prostate cancer antigen 3 gene, also called
DD3 (differential display code 3) which was found to be 10–100
fold over-expressed in 53 of 56 human prostate cancer samples in
a Northern blot analysis whereas it was not expressed in adjacent
non-malignant prostatic tissues[9]. Furthermore, reverse tran-
scription-PCR analysis using PCA3-specific primers indicated that
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tissues and other human malignant tumors, PCA3 is regarded as
one of the most prostate cancer-specific genes described so far.
The current understanding is that the PCA3 gene contains a
high density of stop-codons and expresses a non-coding messenger
RNA in epithelial prostate cells, it functions as a polyadenylated
RNA transcript, but no cytoplasmic protein results from its
transcription. The prostate-specific expression and the sharp up-
regulation of PCA3 mRNA in prostate cancer suggest a unique
transcriptional regulation. As a result, the PCA3 gene promoter
attracted our attention.
We designed a specific primer set to screen the promoter of
PCA3 gene by PCR -based cloning and sequencing with the DNA
extracted from peripheral blood samples of prostate cancer
patients and healthy control individuals. We surprisedly found
that there were short tandem repeat (STR) polymorphisms in the
promoter region of PCA3 gene and the TAAA STR polymorphisms
are significant difference between prostate cancer patients and
healthy control individuals.
Results
A total of 321 subjects, including 186 patients with PCa and
135 healthy individuals as control group from The First Affiliated
Hospital of Wenzhou Medical College, were analyzed for
polymorphisms in promoter of the PCA3 gene. DNA samples
from the blood from individual patients each exhibited a single
band after PCR amplification. The cloning and sequencing assay
revealed a STR in the promoter region of the PCA3 gene. Then
the sequence of the promoter region of the PCA3 gene was
initially screened for polymorphisms by cloning and sequencing
assay in 186 patients with PCa (mean age at diagnosis: 72.33
years; SD: 9.30) and 135 controls (mean age at diagnosis: 71.19
years; SD: 7.39, Table 1). Age at diagnosis did not differ
significantly between the patients and the controls (t=1.20;
P=0.23).
In the present study, five polymorphisms were identified: 4, 5, 6,
7, 8 (the number represents the repeat times of TAAA in the
promoter of PCA3 gene, Fig 1), and eight genotypes were founded.
The 4/5, 4/6, 5/5, 5/6, 5/7, 5/8, 6/6, 6/7 genotypes were
observed in 0.5%, 0.5%, 52.7%, 34.4%, 3.3%, 1.6%, 5.4% and
1.6% of PCa patients, respectively. Whereas only the 5/5, 5/6, 6/
6genotypes were observed in 71.1%, 25.8%, 3.1% of control
subjects, respectively. There was no evidence that the genotype
frequencies deviated from those expected under the Hardy-
Weinberg equilibrium for patients (x
2=1.44, df=3, P=0.70) and
control subjects (x
2=0.14, df=1, P=0.71).
We hypothesized that one TAAA was one unit of the
transcriptional initiation site of PCA3 gene, and TAAA repeats
up-regulated PCA3 transcription, then the same repeat numbers
of TAAA might be associated with the same transcription rate and
the more TAAA repeats, the more PCA3 gene expression. So
based on total number of TAAA repeats in the alleles, eight
genotypes were divided into three groups: #10TAAA,1 1 TAAA,
$12TAAA (e.g. the total TAAA repeat number of genotype
(TAAA)n/(TAAA)m is x[x=n+m],and belongs to the ‘‘x’’ TAAA
group).
Chi-square test showed statistical significance difference in the
construction of PCa and controls between the three groups
(x
2=13.27, df=2, P=0.01), a significant association was observed
between the pooled genotypes and PCa risk. The 11TAAA carrier
was associated with an increased risk for prostate cancer than
individual having #10TAAA (OR=1.76; 95% CI=1.07 – 2.89),
and the $12TAAA carrier was also associated with increased risk
for prostate cancer than individual having #10TAAA (OR=5.28;
95% CI=1.76–15.89, Table 2).
Allele (TAAA) 8 was comparatively rare allele, accordingly,
which leaded the samples in 13TAAA group were rare, study in
larger populations may or may not reveal significant associations
with PCa. These observations suggest that additional work is
needed to determine the functional significance of this region and
the influence of the variability in length and number of TAAA
repeat in future studies with larger patient cohorts.
There was no association between PCA3 promoter STR
polymorphisms and Gleason score in prostate carcinoma patients
(r=0.07, P=0.342, Table 3).
Discussion
Serial analysis of gene expression has shown that PCA3
expression is significantly and especially up-regulated in the
majority of prostatic adenocarcinomas. Therefore, study of genetic
alterations in PCA3 gene may be helpful in elucidating the
pathogenesis of prostate cancer.
Gerald W. Verhaegh et al. previous study has shown that no
known initiator motif, no TATA-box,n oCAAT-box, and no GC-
rich regions were found at consensus positions within the PCA3
promoter. Therefore, novel and tissue-specific cis-acting elements
and trans-acting transcription factors might define the specific and
characteristic expression of PCA3 gene. In their study, a footprint
was found further upstream at position 2173 to 2201 in the PCA3
promoter. Mutation of this A+T-rich region, resulted in a
decreased transcription rate, suggesting a positive role for this
element in PCA3 transcription[10]. In the present study, we
surprisedly found that the A+T-rich region within the PCA3
promoter contained a highly polymorphic region, a STR
polymorphism of (TAAA)n. STRs are repeating DNA sequences
that contain 2 to 6 base-pair units and widespread throughout the
human genome and polymorphic in nature. STRs are important
genetic markers for mapping studies, disease diagnosis and forensic
studies. By screening the A+T-rich region sequence of the
promoter, we identified eight STR polymorphisms and found
the association between those polymorphisms and PCa risk in
Chinese population.
Our results suggested that incidence of PCa was closely related
to the repeat numbers of TAAA in the promoter of PCA3, more
TAAA repeats associated with increased risk for prostate cancer.
In the Chinese population, individuals carrying total 11 repeat
numbers of TAAA in alleles (group 11TAAA) had a 1.76 higher risk
of PCa (95% CI=1.07 – 2.89) than those carrying total #10
repeat numbers of TAAA in alleles (group #10TAAA). The group
Table 1. Clinical characteristics.
Characteristics Cases Controls
Subjects(n) 186 135
Age
a (yr), mean 6 SD 72.3369.30 71.3967.39
Gleason score,n (%)
#6 33(17.74) —
7 52(27.96) —
$8 101(54.30) —
PSA ng/ml, Medians (Q25%–Q75%) 34.60 (7.75–100.00) 0.73(0.44–1.33)
aIndependent-Samples T Test between cases and controls, t=1.20, P=0.23.
doi:10.1371/journal.pone.0020378.t001
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cancer than group #10TAAA (Table 2).
The difference of susceptibility may be related to the difference
in allelic frequencies of PCA3 STR polymorphisms between PCa
patients and controls. It is well known that the expression of PCA3
is very high in the PCa patients than that in healthy individuals.
Owing to the PCA3 promoter has no TATA-box, we hypothesized
that the transcription would begin from other positions. Instead of
TATA-box, the (TAAA)n polymorphic region may be one of the
transcriptional initiation positions. Therefore, the increase of
Table 2. Association between PCA3 promoter STR
polymorphisms and prostate carcinoma risk.
Groups Genotypes
Cases(n)/
controls(n) OR 95%CI P-value
#10TAAA
a,b 4/5,4/6,5/5
c 100/96 1 Ref
11TAAA
a 5/6
c 64/35 1.76 1.07–2.89 0.026
$12TAAA
a 5/7,5/8,6/6,6/7
c 22/4 5.28 1.76–15.89 0.001
a10, 11, 12 and 13 correspond to the total number of TAAA repeat in one allele.
b10TAAA group includes the 9TAAA group.
c4, 5, 6, 7 and 8 correspond to the number of TAAA repeat.
doi:10.1371/journal.pone.0020378.t002
Table 3. Association between PCA3 promoter STR
polymorphism and Gleason score in prostate carcinoma.
Groups Gleason score r
e P-value
#67$8
#10TAAA 21 27 52
11TAAA 8 20 36 0.070 0.342
12TAAA 35 8
13TAAA 10 5
eSpearman’s rank correlation coefficient.
doi:10.1371/journal.pone.0020378.t003
Figure 1. Repressentative PCR -based cloning and sequencing of STR polymorphism in the promoter region of PCA3 gene. A.( TAAA)4
alleles; B.( TAAA)5 alleles; C.( TAAA)6 alleles; D.( TAAA)7 alleles; E.( TAAA)8 alleles.
doi:10.1371/journal.pone.0020378.g001
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transcriptional initiation sites of PCA3 and up-regulated the
expression of PCA3 mRNA in PCa patients. This was in
concordance with our earlier published data [11,12] and the
results of Klecka, J. et al. [9,13–15]. These results revealed that the
polymorphism of TAAA STR in the promoter of PCA3 maybe is a
genetic risk marker for PCa in Chinese population.Of course, this
meaningful conclusions of the reapet times of the TAAA may
modulate PCA3 expression still need the confirmation of
correlation research from different genetic polymorphism types
and the PCA3 mRNA expression in individual or prospective
correlation research.
Our study has a number of important limitations, the most
important of which is its small sample size,so additional larger studies
are needed to provide further insight into these preliminary findings.
It is also important to note that this is a prospective study carried out
in a regional university hospital over five years and cases of PCa
patients arenot very frequent. Since the Chinese populationgenerally
is genetically more homogeneous than other ethnic populations, we
predict similar findings in larger sample sizes across China, but the
applicability of our findings to other ethnic populations will need
further investigation in varying patient populations before these data
can be generally extrapolated to other ethnicities.
In conclusion, our study demonstrates a significant association
between PCA3 promoter STR genetic polymorphisms and PCa in
Chinese populations. These findings indicate that the PCA3
promoter STRs are genetic susceptibility factor for PCa and the
STRs might play a role in the development of this cancer, what
will give clues for a pilot study of carcinogenesis and development
of PCa.
Materials and Methods
Ethics statement
This study was approved by the ethics committee of The First
Affiliated Hospital of Wenzhou Medical College, China, and was
in accordance with the Helsinki declaration. Written informed
consent was obtained from each of the participants at the time of
enrollment.
Study design and patients
For this study, 186 patients with prostate cancer that
underwent surgery in the Department for Surgery at The First
Affiliated Hospital of Wenzhou Medical College between August
2004 and September 2009 were chosen retrospectively. PCa
patients wre confirmed by histopathological evaluation, each
tumor was graded using the Gleason scoring system by two
pathology physicians. In addition, 135 healthy control individuals
were included to determine the distribution of polymorphisms in
a normal population. The controls were selected from men
invited to a systematic health screening, under the proposition of
the national health insurance, performed in the same geograph-
ical areas than the hospitals where the cases were collected. They
were checked by digital rectal examination (DRE), their PSA
value had to be less than 4 ng/ml, and they could exhibit no signs
of PCa. Unfortunately, we do not know that a man with a normal
DRE and a normal PSA will not develop PCa in the future.
Statistically, these observations bias the study against finding a
significant difference between the cases and controls, since some
controls will have prostate carcinoma diagnosed in the future.
While male samples were representative of the general clinical
population, we cannot exclude unreported histories of prostate
disease among the control group. However, such histories should
be no more frequent than in a random, non-urologic clinic
population.
DNA extraction
Five milliliters of venous blood were collected in EDTA as a
source of peripheral blood leukocytes. Genomic DNA was
extracted and purified according to established protocols by using
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany).
Sequencing and analysis of polymorphisms
DNA was extracted from 500 mL of archived whole blood using
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). The
PCA3 promoter was amplified by PCR on the basis of the sequence
of the PCA3 gene presented in GenBank accession number
AL359314.14 and AF279290.1 with Taq polymerase (Qiagen,
Hilden, Germany) with the following primers: 59- GAT GGG
AAC TCA CAT TTG G -39 (forward) and 59- CTG ATG CCA
GCT TCT CG - 39 (reverse). PCRs were performed in 50 mL
reaction mix containing 1 mL of extracted DNA; 5 mL1 0 XPCR
Buffer (100 mmol/L Tris-HCL (pH 9.2)); 3 mL MgCl2(25 mmol/
L); 5 mL dNTP (2 mmol/L); 2 mL forward and reverse primer
(5 mmol/L), respectively; 0.4 mL Taq-polymerase; and 31.6 mL
distilled water. PCR conditions were as follows: 95uC for 4
minutes and then 40 cycles of 95uC for 1 minute, 60uC for 30
seconds, 72uC for 1 minute, and followed by extension at 72uC for
10 minutes. All PCR products were electrophoresed on a 1.5%
agarose gel. Amplified fragments were purified by QIAquick Spin
PCR Purification Kit (Qiagen, Hilden, Germany),then were sent
to Invitrogen Corporation in Shanghai for cloning and sequencing
assay with no information on the specimens and knowledge of the
study.
Statistical Analysis
We used the Statistical Package for Social Sciences for Windows
(version 13.0; SPSS Inc, Chicago, IL, USA) for statistical analysis.
The values for age are reported as mean6SD. Statistical analysis
of age was performed by the unpaired t-test. A chi-square test was
applied for cross-table analysis. Genotype-specific risks were
estimated as odds ratios (ORs) with associated 95% confidence
intervals (CIs) by chi-square test possible deviation of the genotype
frequencies from PCa and controls expected under Hardy-
Weinberg equilibrium was assessed by the chi-square test.
Spearman’s rank correlation tests was used to assess whether
there is a relationship between PCA3 promoter STR polymor-
phism and Gleason score in PCa. Significance statements refer to
P values of 2-tailed tests that were less than 0.05.
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